Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007...
Hence then, the article about whitehawk therapeutics expands adc pipeline with new option agreement for use of cpt113 linker payload was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload )
Also on site :
- We Asked 3 Oncologists About the Worst Thing You Can Do for Cancer Risk and They All Said the Same Thing
- ‘What a joke’: Github Copilot’s new token-based billing spurs consternation among devs
- Box Office: ‘Backrooms’ Scares Up $38 Million on Friday, Already Shattering Record for A24’s Best Opening Weekend